Linked Life Data

20571433

Source:http://linkedlifedata.com/resource/pubmed/id/20571433

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-7-15
pubmed:abstractText
To compare the efficacy and tolerability of antidepressants switch with extended-release venlafaxine (venlafaxine-XR), mirtazapine, and paroxetine in Chinese patients with major depressive disorder who had 2 consecutive unsuccessful antidepressant trials. One hundred fifty adult patients with treatment-resistant depression according to their medical records and/or response to current treatments were randomly assigned to receive fixed-dosage treatment of venlafaxine-XR 225 mg/d (n = 50), mirtazapine 45 mg/d (n = 55), or paroxetine 20 mg/d (n = 45) for 8 weeks. The primary outcome was the remission rates that were defined as a score 7 or lower on the 17-item Hamilton Rating Scale for Depression (HRSD-17). Secondary outcomes included the remission rate defined by the Self-Rating Depression Scale of 50 or lower and the response rate defined by a 50% reduction or greater on the HRSD-17 total score, and the improvement of patients' general health functions. The completion rates were 82% for venlafaxine-XR, 81.8% for mirtazapine, and 82.2% for paroxetine. Only one patient in paroxetine arm discontinued the study owing to an adverse event. The remission rates based on the HRSD-17 were 42.0% for venlafaxine-XR, 36.4% for mirtazapine, and 46.7% for paroxetine. There were no statistical significances between treatment arms in remission rates. Similarly, there were also no significant differences between groups in secondary outcome measure. Venlafaxine-XR, mirtazapine, and paroxetine were equally effective in the treatment of Chinese patients with major depressive disorder who failed at least 2 previous antidepressant treatments. Selecting any of these 3 antidepressants as a third-step antidepressant is a reasonable choice for this group of patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1533-712X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
357-64
pubmed:meshHeading
pubmed-meshheading:20571433-Adult, pubmed-meshheading:20571433-Antidepressive Agents, Second-Generation, pubmed-meshheading:20571433-Antidepressive Agents, Tricyclic, pubmed-meshheading:20571433-China, pubmed-meshheading:20571433-Cyclohexanols, pubmed-meshheading:20571433-Delayed-Action Preparations, pubmed-meshheading:20571433-Depressive Disorder, Major, pubmed-meshheading:20571433-Double-Blind Method, pubmed-meshheading:20571433-Drug Resistance, pubmed-meshheading:20571433-Female, pubmed-meshheading:20571433-Humans, pubmed-meshheading:20571433-Male, pubmed-meshheading:20571433-Mianserin, pubmed-meshheading:20571433-Middle Aged, pubmed-meshheading:20571433-Paroxetine, pubmed-meshheading:20571433-Pilot Projects, pubmed-meshheading:20571433-Psychiatric Status Rating Scales, pubmed-meshheading:20571433-Remission Induction, pubmed-meshheading:20571433-Treatment Outcome
pubmed:year
2010
pubmed:articleTitle
Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
pubmed:affiliation
Shanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, Shanghai, China. yirufang@yahoo.com.cn
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study